Biotechnology, vaccines, and public health by Emergent Biosolutions

Emergent Biosolutions announced it has received a modification exercising an option period under its existing delivery order with the U.S. Department of War, valued at up to 22.3 million dollars. ...

Emergent Biosolutions has announced that it will hold its third quarter 2026 earnings call on Monday, November 2, at 5:00 p.m. eastern time. The company invited investors and stakeholders to ...

Emergent Biosolutions has restarted manufacturing operations at its Canton facility. The company marked the occasion with a celebration attended by President and CEO Joseph Papa and Secretary Eric ...

Emergent Biosolutions announced the completion of a repurchase totaling 75 million dollars in aggregate principal amount of senior unsecured notes. The company stated management will discuss ...

Emergent Biosolutions has been awarded a standing offer by the Government of Canada to supply NARCAN Nasal Spray, following a competitive procurement process. The agreement strengthens the ...

Emergent Biosolutions is calling for a new approach to global health readiness that combines strategic stockpiling with the capability for surge manufacturing. In its latest white paper, the ...

Emergent Biosolutions urges that true preparedness against intensifying global biological threats requires more than just stockpiling resources. The company advocates for a dual strategy that ...

Emergent Biosolutions announced efforts to enhance product availability aimed at protecting communities worldwide. The company stated its approach relies on scientific rigor, quality, compliance, ...

Emergent Biosolutions has reaffirmed its commitment to bolstering protection for Americans by enhancing preparedness strategies against potential biological threats. The company stated that ...

Emergent Biosolutions, together with PANTHER Health and Africa CDC, has initiated the MpOx Study in Africa (MOSA), with the first patient enrolled in Madagascar. The launch follows a recent ...

Emergent Biosolutions has published research in Clinical and Translational Science evaluating the safety and pharmacokinetics of multiple-dose intranasal naloxone. The findings contribute ...

Emergent Biosolutions announced its commitment to developing, manufacturing, and delivering products aimed at protecting communities globally. The company’s strategy is centered on scientific ...

Emergent Biosolutions announced it has received a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR) to support its ...

Emergent Biosolutions has supplied its medical countermeasures to more than 20 countries, strengthening international efforts to protect public health. The company stated that these deliveries ...

Emergent Biosolutions has announced the donation of thousands of units of NARCAN Nasal Spray throughout the U.S. since 2021. The company referenced its ongoing commitment to social responsibility ...

Emergent Biosolutions is working with governments worldwide to strengthen preparedness for major health threats, including pandemics and bioterrorism. The company focuses on providing solutions ...